by Richard Cruse | Feb 6, 2025 | Press releases
ProFactor Pharma Ltd. (PFP), a UK biotech company, is pleased to announce it has been awarded a SMART: SCOTLAND grant from Scottish Enterprise. This grant has been awarded to perform a preclinical Proof-of-Concept study of a novel approach to significantly improve the...
by Richard Cruse | Apr 11, 2024 | Events
On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day. The theme of the event this year is “Equitable access for all: recognizing all bleeding disorders”. The World Federation...
by Richard Cruse | Jul 10, 2023 | News
ProFactor Pharma Ltd (PFP) is excited to welcome Eugenia Wachters, who joined the company as Chief Operating Officer on 1st July 2023. Eugenia will be responsible for leading the company’s business operations, working closely with the PFP Executive team and Board...
by Richard Cruse | Apr 19, 2023 | News
The World Federation of Hemophilia (WFH) have set April 17, 2023 as World Hemophilia Day. The theme of the event this year is “Access for All: Prevention of bleeds as the global standard of care”. Building on last year’s theme, the call to action for the community in...
by Richard Cruse | Sep 20, 2022 | News
ProFactor Pharma is pleased to announce completion of a further investment round. The investment will enable PFP to progress the company’s clinical stage Recombinant Human Factor VIII to market and to engage with commercial licensing opportunities. The funding...
by Richard Cruse | Nov 24, 2021 | News
Published on November 23, 2021 By Deborah Johnson Interview: Ending the haemophilia drug shortage Jaymin Amin, CEO of ProFactor Pharma (PFP), discusses the company’s life-changing, and lifesaving, work. PFP says it has developed a low-cost production process for...
by Richard Cruse | Mar 31, 2021 | News
ProFactor Pharma Ltd (PFP) the developer of a unique, ultra high yielding cell line for the manufacture of recombinant human factor VIII (rhVIII), is pleased to announce the recent issuance of Indian Patent No. 361851 and Eurasian Patent No 529615EA. This patent...
by Richard Cruse | Jan 31, 2021 | News
Scottish biotech business ProFactor Pharma Ltd: (PFP) has completed the optimisation of its process for the manufacture of recombinant Factor VIII, for the treatment of Haemophilia A. In July 2020 we reported on the important development milestone that had been...
by Richard Cruse | Jan 19, 2021 | News
A year on from my last analysis of the World Federation for Hemophilia (WFH) Report on the Annual Survey we see in 2019 a further improvement in the number of people treated. However, we also see new data on the prevalence of the haemophilia A which suggests there are...
by Richard Cruse | Jul 15, 2020 | News
ProFactor Pharma Ltd (PFP), has completed an important development milestone in its programme to transform the treatment of ‘Haemophilia A’. The company has now received the second tranche of funding from its £2m funding round announced in September 2019 to advance...
